| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
Resomelagon (0-1000 μM; 8 minutes; HEK293A cells) stimulates Ca2+ and phosphorylates ERK1/2 to enhance melanobasin signaling [1]. Resomelagon possesses anti-inflammatory properties (1 nM; 30 min; peritoneal macrophages).
|
|---|---|
| ln Vivo |
Resomelagon (zero to ten milligrams per kilogram; intraperitoneal, intravenous, intravenous; 24-hour; furnished with electrodes for both BALB/c and C57BL/6J wild-type (WT) and WT cells) facilitates the resolution of acute inflammation in the body [1]. Mice's arthritis is reduced by resomelagon (25) - 50 mg/kg; mouse; once daily for 8 days; male C57BL/6J wild-type (WT) and BALB/c mice [1].
|
| Cell Assay |
Western Blot analysis [1]
Cell Types: HEK293A Cell Tested Concentrations: 0-1000 μM Incubation Duration: 8 min Experimental Results: ERK1/2 phosphorylation in dose- Increases expression and inhibits TNF-α release and cell vomiting [1]. Dependence method. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6J wild-type (WT) and balb/c (Bagg ALBino) mouse [1]
Doses: 0, 0.1, 1, and 10 mg/kg Route of Administration: po (po (oral gavage)) intraperitoneal, and intravenous (iv) (iv)injection; 24-hour Experimental Results: Inhibits neutrophil and monocyte infiltration in a dose-dependent manner. Animal/Disease Models: Male C57BL/6J wild-type (WT) and balb/c (Bagg ALBino) mouse [1] Doses: 25 and 50 mg/kg Route of Administration: Oral; daily; for 8 days Experimental Results: Reduction in all joints measured symptoms of inflammation, including clinical score (-42%), paw swelling (-87%), proportion of animals with all four paws affected (-50%), and severity of inflammation (-70%). |
| References |
| Molecular Formula |
C14H14N6O2
|
|---|---|
| Molecular Weight |
298.30
|
| Exact Mass |
298.117
|
| CAS # |
1809420-71-0
|
| Related CAS # |
Resomelagon acetate;1809420-72-1
|
| PubChem CID |
23728926
|
| Appearance |
Light brown to brown solid powder
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
466
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C2C=CC=CC=2[N+]([O-])=O)C(/C=C/C=N/NC(N)=N)=CC=C1
|
| InChi Key |
ZSDGHWLLLGYAJV-AHEHSYJASA-N
|
| InChi Code |
InChI=1S/C14H14N6O2/c15-14(16)18-17-9-3-5-11-6-4-10-19(11)12-7-1-2-8-13(12)20(21)22/h1-10H,(H4,15,16,18)/b5-3+,17-9+
|
| Chemical Name |
2-[(E)-[(E)-3-[1-(2-nitrophenyl)pyrrol-2-yl]prop-2-enylidene]amino]guanidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~335.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (16.76 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (16.76 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3523 mL | 16.7616 mL | 33.5233 mL | |
| 5 mM | 0.6705 mL | 3.3523 mL | 6.7047 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
